RT Journal Article
SR Electronic
T1 Integration of proteomics with genomics and transcriptomics increases the diagnostic rate of Mendelian disorders
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.09.21253187
DO 10.1101/2021.03.09.21253187
A1 Kopajtich, Robert
A1 Smirnov, Dmitrii
A1 Stenton, Sarah L.
A1 Loipfinger, Stefan
A1 Meng, Chen
A1 Scheller, Ines F.
A1 Freisinger, Peter
A1 Baski, Robert
A1 Berutti, Riccardo
A1 Behr, Jürgen
A1 Bucher, Martina
A1 Distelmaier, Felix
A1 Graf, Elisabeth
A1 Gusic, Mirjana
A1 Hempel, Maja
A1 Kulterer, Lea
A1 Mayr, Johannes
A1 Meitinger, Thomas
A1 Mertes, Christian
A1 Metodiev, Metodi D.
A1 Nadel, Agnieszka
A1 Nasca, Alessia
A1 Ohtake, Akira
A1 Okazaki, Yasushi
A1 Olsen, Rikke
A1 Piekutowska-Abramczuk, Dorota
A1 Rötig, Agnès
A1 Santer, René
A1 Schindler, Detlev
A1 Slama, Abdelhamid
A1 Staufner, Christian
A1 Strom, Tim
A1 Verloo, Patrick
A1 von Kleist-Retzow, Jürgen-Christoph
A1 Wortmann, Saskia B.
A1 Yépez, Vicente A.
A1 Lamperti, Costanza
A1 Ghezzi, Daniele
A1 Murayama, Kei
A1 Ludwig, Christina
A1 Gagneur, Julien
A1 Prokisch, Holger
YR 2021
UL http://medrxiv.org/content/early/2021/07/03/2021.03.09.21253187.abstract
AB By lack of functional evidence, genome-based diagnostic rates cap at approximately 50% across diverse Mendelian diseases. Here, we demonstrate the effectiveness of combining genomics, transcriptomics, and, for the first time, proteomics and phenotypic descriptors, in a systematic diagnostic approach to discover the genetic cause of mitochondrial diseases. On fibroblast cell lines from 145 individuals, tandem mass tag labelled proteomics detected approximately 8,000 proteins per sample and covered over 50% of all Mendelian disease-associated genes. Aberrant protein expression analysis allowed the validation of candidate protein-destabilising variants, in addition to providing independent complementary functional evidence to variants leading to aberrant RNA expression. Overall, our integrative computational workflow led to genetic resolution for 22% of 121 genetically unsolved whole exome or whole genome negative cases and to the discovery of two novel disease genes. With increasing democratization of high-throughput omics assays, our approach and code provide a blueprint for implementing multi-omics based Mendelian disease diagnostics in routine clinical practice.Competing Interest StatementA.O. declares a consigned research fund (SBI Pharmaceuticals Co., Ltd.). All other authors declare no conflict of interest.Funding StatementThis study was supported by a German Federal Ministry of Education and Research (BMBF, Bonn, Germany) grant to the German Network for Mitochondrial Disorders (mitoNET, 01GM1906D), the German BMBF and Horizon2020 through the E-Rare project GENOMIT (01GM1920A), the ERA PerMed project PerMiM (01KU2016A), the German BMBF through the e:Med Networking fonds AbCD-Net (FKZ 01ZX1706A), the German Research Foundation/Deutsche Forschungsgemeinschaft (DI 1731/2-2), the AFM-Telethon grant (#19876), the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development, AMED (JP19ek0109273, JP20ek0109468, JP20kk0305015, JP20ek0109485), a CMHI grant (S145/16), a PMU-FFF grant (A-20/01/040-WOS), the Pierfranco and Luisa Mariani Foundation (CM23), and the Italian Ministry of Health (GR-2016-02361494, GR-2016-02361241).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All individuals included in the study or their legal guardians provided written informed consent before evaluation, in agreement with the Declaration of Helsinki and approved by the ethical committees of the centres participating in this study, where biological samples were obtained. All studies were completed according to local approval of the ethical committee of the Technical University of Munich.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe proteomic raw data and MaxQuant search files have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository and can be accessed using the dataset identifier PXD022803. Code to reproduce the analysis is available via GitHub at github.com/prokischlab/omicsDiagnostics/. https://github.com/prokischlab/omicsDiagnostics/